Alexion Pharmaceuticals Stock News

EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

Fast-growing AstraZeneca might make an interesting addition to your portfolio.

AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in

The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Comp

The deal, which would be financed by a $25 billion capital increase once it is concluded, was approved by AstraZeneca shareholders two weeks ago.

The deal has already been approved by the U.S. and Canadian authorities.

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or else

BOSTON--(BUSINESS WIRE)--Alexion Shareholders Approve Acquisition by AstraZeneca

Elfun Trusts (Trades, Portfolio), part of Boston-based State Street Global Advisors, disclosed this week that its top five trades during the first quarter included a new position in Regions Financial

Alexion (ALXN) delivered earnings and revenue surprises of 14.29% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 9.32% year over year to $3.5

Alexion Pharmaceuticals (NASDAQ:ALXN) unveils its next round of earnings this Friday, April 30. Here is Benzinga's everything-that-matters guide for the earnings announcement.

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financ